Frieda Wolf, M.D., and Eli A. Friedman, M.D.

Dr. Wolf is Transplant Fellow, Renal Disease Division, SUNY Health Sciences, Brooklyn, New York.

Dr. Wolf reports no conflict of interest. Within the past three years, Dr. Friedman has received grant/research support from Alteon.

Release Date: 07/22/2003
Termination Date: 07/22/2006

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

• Describe the growing epidemic of chronic kidney disease in the United States
• Discuss the measures that hold promise of slowing the course of progressive kidney damage
• Assess whether proteinuria, by inciting release of proinflammatory cytokines, recruits monocytes thereby injuring the kidney
• Assess the necessity for employing treatments for kidney diseases such as angiotensin converting enzyme inhibitors and receptor blockers that reduce the amount of proteinuria.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity